| |
 |
Hypoxia: Targeting the Tumour
|
| |
|
pp.281-286 (6) Authors: Robert George Boyle, Stuart Travers |
| |
|
|
| |
|
From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
|
| |
|
pp.287-301 (15) Authors: Barbara Gatto, Marco Cavalli |
| |
|
|
| |
|
Syntheses, Molecular Targets and Antitumor Activities of Novel Triptycene Bisquinones and 1,4-Anthracenedione Analogs
|
| |
|
pp.303-318 (16) Authors: Duy H. Hua, Kaiyan Lou, Srinivas K. Battina, Huiping Zhao, Elisabeth M Perchellet, Yang Wang, Jean-Pierre H. Perchellet |
| |
|
|
| |
|
Potential of Cyclopenta[b]benzofurans from Aglaia Species in Cancer Chemotherapy
|
| |
|
pp.319-345 (27) Authors: Soyoung Kim, Angela A. Salim, Steven M. Swanson, A. Douglas Kinghorn |
| |
|
|
| |
|
Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
|
| |
|
pp.347-365 (19) Authors: Tsui-Hwa Tseng, Yean-Jang Lee |
| |
|
|
| |
|
Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity
|
| |
|
pp.367-375 (9) Authors: Ivana Barbosa Suffredini, Antonio Drauzio Varella, Riad Naim Younes |
| |
|
|
| |
|
Chk1 Inhibitors for Novel Cancer Treatment
|
| |
|
pp.377-388 (12) Authors: Zhi-Fu Tao, Nan-Horng Lin |
| |
|
|
